A Randomized Phase 2 Study of Adjunctive EQU-001 for Uncontrolled Focal Onset Seizures
Latest Information Update: 26 Dec 2023
At a glance
- Drugs EQU-001 (Primary)
- Indications Partial epilepsies; Seizures
- Focus Therapeutic Use
- Sponsors Equilibre Biopharmaceuticals
Most Recent Events
- 15 Dec 2023 Status changed from recruiting to discontinued due to lack of sufficient funding for study completion.
- 18 May 2023 Planned End Date changed from 1 Jan 2027 to 1 Oct 2025.
- 18 May 2023 Planned primary completion date changed from 1 Jan 2025 to 1 Oct 2024.